Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GLAUKOS CORPORATION

(GKOS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
45.37(c) 45.93(c) 46.27(c) 45.78(c) 45.15 Last
416 170 374 294 233 911 237 626 81 464 Volume
+1.23% +1.23% +0.74% -1.06% -1.38% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 288 M - -
Net income 2021 -60,8 M - -
Net Debt 2021 74,8 M - -
P/E ratio 2021 -35,6x
Yield 2021 -
Sales 2022 266 M - -
Net income 2022 -75,7 M - -
Net Debt 2022 123 M - -
P/E ratio 2022 -26,4x
Yield 2022 -
Capitalization 2 130 M 2 130 M -
EV / Sales 2021 7,66x
EV / Sales 2022 8,46x
Nbr of Employees 653
Free-Float 96,1%
More Financials
Company
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company that is focused on developing therapies for the treatment of glaucoma, corneal disorders, and retinal disease. The Company’s products are designed to treat mild-to-moderate open-angle glaucoma, the iStent, the iStent inject, and the iStent inject W. The Company’s Micro-Invasive Glaucoma Surgery (MIGS) serves as an alternative to... 
More about the company
Ratings of Glaukos Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about GLAUKOS CORPORATION
10/14GLAUKOS CORPORATION : to Release Third Quarter 2021 Financial Results after Market Close o..
BU
10/07GLAUKOS : Technologies Featured in Numerous Scientific Abstracts at the 2021 European Soci..
BU
09/20GLAUKOS : Signs Licensing Deal With Attillaps
MT
09/20GLAUKOS : Announces Licensing Agreement with Attillaps Holdings, Inc.
BU
09/15Health Care Stocks Edge Higher Premarket Wednesday
MT
09/15GLAUKOS : Agrees to Stop Patent Litigation Against Ivantis in Exchange for $60 Million Pay..
MT
09/15GLAUKOS CORP : Other Events (form 8-K)
AQ
09/15GLAUKOS : Announces Settlement of Patent Litigation with Ivantis, Inc.
BU
09/03GLAUKOS : Says it Submitted Supplemental Pre-Market Approval Application for Investigation..
MT
09/03GLAUKOS : Announces Submission of Supplemental Pre-Market Approval Application for iStent ..
BU
09/03Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent..
CI
08/26GLAUKOS : Announces Participation in the Wells Fargo Healthcare Conference
BU
08/23GLAUKOS : Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on..
BU
08/18GLAUKOS CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
08/09INSIDER TRENDS : Glaukos Insider Granted Stock Award, Trend of Buys Extended
MT
More news
News in other languages on GLAUKOS CORPORATION
2017Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on GLAUKOS CORPORATION
More recommendations
Chart GLAUKOS CORPORATION
Duration : Period :
Glaukos Corporation Technical Analysis Chart | GKOS | US3773221029 | MarketScreener
Technical analysis trends GLAUKOS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 45,78 $
Average target price 50,56 $
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Thomas William Burns President, Chief Executive Officer & Director
Joseph E. Gilliam CFO, CAO & Senior VP-Corporate Development
William J. Link Chairman
L. Jay Katz Chief Medical Officer
Tomas Navratil Senior Vice President-Research & Development
Sector and Competitors